Gabriel J. Robbie

Medicine · Health Sciences

27h-index3.5kcitations59works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(14), Respiratory viral infections research(9), Porphyrin Metabolism and Disorders(8), Systemic Lupus Erythematosus Research(7), Neonatal Respiratory Health Research(6)

Publications59 total

Model-Based Evaluation of Lumasiran Plasma and Liver Pharmacokinetics in Non-Human Primates
2026Open Access
Platform Assessment of Concentration–QTc Relationship Across GalNAc–siRNA Molecules
Clinical Pharmacokinetics·2025Open Access
Disease Progression Modeling of Stargardt’s disease
2024Open Access
Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
2024Open Access
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
Clinical Pharmacokinetics·2023· 4 cited
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
New England Journal of Medicine·2023· 235 citedOpen Access
Quantification of Oxalate by Novel LC–MS/MS: Assay Development, Validation and Application in Lumasiran Clinical Trials
Bioanalysis·2023· 7 citedOpen Access
Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria
CPT Pharmacometrics & Systems Pharmacology·2023· 4 citedOpen Access
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria
Clinical Pharmacokinetics·2023· 4 cited
Quantification of Oxalate in Human Plasma by Novel Liquid Chromatography-Tandem Mass Spectrometry: Method Development, Validation, and Application in Lumasiran Clinical Trials
Journal of the American Society of Nephrology·2022
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
Clinical Pharmacokinetics·2022Open Access
FC069: Pharmacokinetics and Pharmacodynamics of Lumasiran: Analysis of Four Clinical Studies
Nephrology Dialysis Transplantation·2022
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
Drugs in R&D·2021· 28 citedOpen Access
A Drug‐Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver
Clinical Pharmacology & Therapeutics·2021· 27 cited
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human
Drug Metabolism and Disposition·2021· 97 citedOpen Access
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
Clinical Pharmacokinetics·2020· 73 citedOpen Access
Normal reference ranges for urinary δ‐aminolevulinic acid and porphobilinogen levels
JIMD Reports·2020· 14 citedOpen Access
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
Clinical Pharmacology & Therapeutics·2020· 159 cited
Population Pharmacokinetic–Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration
Nucleic Acid Therapeutics·2020· 25 citedOpen Access
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria
Clinical Pharmacology & Therapeutics·2020· 99 cited
page 1 of 3Next →

Frequent Co-authors

Valerie A. Clausen(8), Varun Goel(7), Lorin Roskos(6), Genevieve A. Losonsky(5), Wendy I. White(5), Xiang‐Qing Yu(5), Bahru Habtemariam(5), Barbara White(4), Megan Melch(4), Win L. Chiou(4), Kathryn Jensen(3), Warren Greth(3), Marianne T. Sweetser(3), Hasan S. Jafri(3), Sagar Agarwal(3), Amy Simon(3), Yuanxin Xu(3), Song Ren(3), Patricia C. Ryan(3), Prajakta Badri(3)